Chat with us

Empagliflozin 25 mg brands in India : Steris Pharm...

Empagliflozin 25 mg brands in India : Steris Pharma.

GLIEMPAFLOZIN 25 is a powerful medication used primarily for the management of type 2 diabetes mellitus. The active ingredient, Empagliflozin, is a member of the SGLT2 inhibitor class, which is a group of medications known for their ability to regulate blood glucose levels in individuals with diabetes. Empagliflozin works by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion through urine, thereby lowering blood sugar levels. Additionally, GLIEMPAFLOZIN 25 provides cardiovascular and renal benefits, making it a valuable treatment for patients with type 2 diabetes who are at risk of heart disease or kidney problems.

Key Features and Ingredients

GLIEMPAFLOZIN 25 contains 25mg of Empagliflozin as its active ingredient. Empagliflozin is a selective Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor, which works by blocking the reabsorption of glucose from the kidneys back into the bloodstream. By doing so, it promotes the elimination of excess glucose through urine, thereby lowering blood sugar levels and improving overall glycemic control.

Ingredients:

Active Ingredient: Empagliflozin (25mg)
Inactive Ingredients: These may include excipients such as lactose, microcrystalline cellulose, magnesium stearate, and others that help in the formulation and stability of the tablet.

Usage

GLIEMPAFLOZIN 25 is primarily used in the management of type 2 diabetes mellitus. It is typically prescribed in combination with other antidiabetic medications to enhance blood sugar control. The usual starting dose for Empagliflozin is 25mg once daily, but the dosage may be adjusted depending on individual needs, response, and tolerability. The tablet can be taken with or without food, and it is essential to follow the doctor's instructions carefully for optimal results.

Benefits of GLIEMPAFLOZIN 25

Effective Blood Sugar Control:
The primary benefit of GLIEMPAFLOZIN 25 is its ability to help lower blood sugar levels in people with type 2 diabetes. By inhibiting the action of SGLT2 in the kidneys, Empagliflozin promotes the excretion of excess glucose through urine, thus reducing blood glucose and improving overall glycemic control. This is essential for managing type 2 diabetes and preventing complications associated with high blood sugar.
Cardiovascular Protection:
GLIEMPAFLOZIN 25 is particularly beneficial for type 2 diabetes patients who are at high risk of cardiovascular diseases. Clinical studies have shown that Empagliflozin reduces the risk of cardiovascular death, hospitalization for heart failure, and other major cardiovascular events. This makes it an excellent choice for individuals who have both diabetes and heart disease or are at risk for these conditions.
Renal Health Benefits:
For individuals with diabetic kidney disease or those at risk of kidney complications, GLIEMPAFLOZIN 25 provides significant renal benefits. It helps in protecting kidney function, slowing the progression of kidney disease, and reducing the risk of kidney failure. The medication reduces the amount of glucose reabsorbed by the kidneys, which helps protect the kidneys from damage caused by prolonged high blood sugar levels.
Weight Loss Support:
GLIEMPAFLOZIN 25 can also assist with weight loss. The increased glucose excretion through urine leads to a slight reduction in body weight, which is an important factor in managing type 2 diabetes. This weight loss benefit, coupled with improved blood sugar control, enhances overall health outcomes.
Low Risk of Hypoglycemia:
Unlike some other diabetes medications, GLIEMPAFLOZIN 25 does not carry a high risk of hypoglycemia (dangerously low blood sugar). Since it works by removing excess glucose through urine rather than stimulating insulin production, it does not cause a drop in blood sugar levels that can lead to hypoglycemic episodes, making it a safer option for many patients.
Convenient Once-Daily Dosage:
With a once-daily dosage of 25mg, GLIEMPAFLOZIN 25 offers a convenient and simple treatment regimen for managing type 2 diabetes. This ease of use increases patient compliance with the treatment plan, helping them achieve better blood sugar control.

Conclusion

GLIEMPAFLOZIN 25 is an effective medication for managing type 2 diabetes mellitus and offers multiple benefits beyond blood sugar control. With its active ingredient, Empagliflozin (25mg), it helps lower blood glucose levels, offers cardiovascular protection, supports renal health, and aids in weight loss. Additionally, it carries a low risk of hypoglycemia, making it a safe and practical treatment option for individuals with type 2 diabetes. Its convenient once-daily dosage and wide-ranging benefits make GLIEMPAFLOZIN 25 a valuable medication for those needing comprehensive management of their diabetes. Always consult with your healthcare provider to determine the best course of treatment tailored to your specific needs.Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options. The company offers a wide range of healthcare products, catering to various medical needs, from rare disease treatments to essential healthcare products. Sterispharma's product range includes solutions for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. Medicines can be conveniently ordered via Our websites—Sterisonline, Sterisindia, and Sterispharma.